Abstract

INTRODUCTION

In this retrospective study, we aimed to evaluate the clinical and histopathological features and survival rates of patients with localized gastrointestinal stromal tumors (GIST).

METHODS

Between April 2004 and October 2014, 94 patients diagnosed with GIST who were referred to the Department of Medical Oncology, Ankara Numune Education and Research Hospital were retrospectively reviewed. A total of 65 nonmetastatic operable GIST patients were included in the study.

RESULTS

The median age was 53 years (22-78) and most patients were male (male/female: 41/24). The most common localization of tumors were stomach (58.5%), non-gastric gastrointestinal (29.2%), and ekstragastrointestinal (12.3%). According to the AFIP prognostic criteria, 24.6% of patients was located in low risk group, 21.5% in intermediate risk group, and 53.9% in high risk group. Only 33.8% of patients received adjuvant imatinib treatment. While the median overall survival (OS) was not reached, 3 year and 2 year disease free survival (DFS) was 81% and 84% respectively. There was no statistically significant difference neither in 2 year DFS nor in 3 year DFS according to gender, tumor site, tumor size, mitotic count, CD34, AFIP risk group and adjuvant treatment.

DISCUSSION AND CONCLUSION

The median OS was not reached in localized GIST patients who underwent surgery, whereas a high DFS rate was found.